Intra-Cellular Therapies, Inc. (ITCI) Ownership

$131.87

south_east
-$0 (0%)
Day's range
$131.87
Day's range
$131.87

Intra-Cellular Therapies, Inc. Major Shareholders & Ownership History

Major Shareholder Name Reporting Date Shares Held Market Value Change in Shares Ownership
FMR LLC 02/13/2025 11.08 M $925.10 M   -0.41% 10.47%
VANGUARD GROUP INC 02/11/2025 9.72 M $811.93 M   0.97% 9.19%
BLACKROCK, INC. 02/07/2025 6.11 M $510.53 M   -1.71% 5.78%
JPMORGAN CHASE & CO 02/12/2025 5.13 M $428.13 M   -3.03% 4.85%
WASATCH ADVISORS LP 02/13/2025 3.25 M $271.34 M   -15.58% 3.07%
NORGES BANK 02/12/2025 3.21 M $268.35 M   100.00% 3.04%
INVESCO LTD. 02/13/2025 3.08 M $257.01 M   2.93% 2.91%
AVORO CAPITAL ADVISORS LLC 02/14/2025 3.05 M $254.74 M   0.00% 2.88%
BELLEVUE GROUP AG 02/14/2025 2.44 M $203.81 M   -1.83% 2.31%
DEEP TRACK CAPITAL, LP 02/14/2025 2.00 M $167.04 M   24.95% 1.89%
STATE STREET CORP 02/14/2025 1.87 M $156.59 M   0.86% 1.77%
FRANKLIN RESOURCES INC 02/12/2025 1.78 M $148.41 M   1.35% 1.68%
GEODE CAPITAL MANAGEMENT, LLC 02/12/2025 1.72 M $143.43 M   0.50% 1.62%
CLEARBRIDGE INVESTMENTS, LLC 02/12/2025 1.69 M $140.85 M   -2.51% 1.59%
PICTET ASSET MANAGEMENT HOLDING SA 02/12/2025 1.54 M $128.66 M   -4.87% 1.46%
SUVRETTA CAPITAL MANAGEMENT, LLC 02/14/2025 1.44 M $120.19 M   0.00% 1.36%
GW&K INVESTMENT MANAGEMENT, LLC 02/05/2025 1.39 M $115.88 M   -0.48% 1.31%
PERCEPTIVE ADVISORS LLC 02/14/2025 1.29 M $107.60 M   -20.58% 1.22%
WESTFIELD CAPITAL MANAGEMENT CO LP 02/11/2025 1.22 M $101.79 M   5.12% 1.15%
HOLOCENE ADVISORS, LP 02/14/2025 1.20 M $100.08 M   -12.59% 1.13%
MARSHALL WACE, LLP 02/13/2025 1.08 M $90.18 M   -7.00% 1.02%
ALLIANCEBERNSTEIN L.P. 02/12/2025 1.06 M $88.24 M   -12.56% 1.00%
WELLINGTON MANAGEMENT GROUP LLP 02/12/2025 1.03 M $86.34 M   1.58% 0.98%
RAYMOND JAMES FINANCIAL INC 02/13/2025 915,361 $76.45 M   100.00% 0.87%
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 02/06/2025 906,646 $75.72 M   0.19% 0.86%
MORGAN STANLEY 02/14/2025 892,386 $74.53 M   6.72% 0.84%
TIMESSQUARE CAPITAL MANAGEMENT, LLC 02/03/2025 840,269 $70.18 M   91.81% 0.79%
DEUTSCHE BANK AG\ 02/14/2025 776,028 $64.81 M   -10.47% 0.73%
FIRST TRUST ADVISORS LP 02/13/2025 766,134 $63.99 M   12.63% 0.72%
SCHRODER INVESTMENT MANAGEMENT GROUP 02/12/2025 743,230 $62.04 M   -19.58% 0.70%
ADAGE CAPITAL PARTNERS GP, L.L.C. 02/14/2025 678,000 $56.63 M   266.49% 0.64%
HOOD RIVER CAPITAL MANAGEMENT LLC 02/14/2025 615,161 $51.38 M   2.53% 0.58%
NORTHERN TRUST CORP 02/14/2025 609,777 $50.93 M   23.96% 0.58%
PRICE T ROWE ASSOCIATES INC /MD/ 02/14/2025 589,906 $49.27 M   -43.41% 0.56%
PRINCIPAL FINANCIAL GROUP INC 01/31/2025 550,963 $46.02 M   -7.82% 0.52%
MACQUARIE GROUP LTD 02/14/2025 544,532 $45.48 M   -22.95% 0.51%
AQR CAPITAL MANAGEMENT LLC 02/14/2025 536,781 $44.83 M   16.23% 0.51%
D. E. SHAW & CO., INC. 02/14/2025 534,461 $44.64 M   44.97% 0.51%
AMERIPRISE FINANCIAL INC 02/14/2025 522,563 $43.64 M   -1.44% 0.49%
MILLENNIUM MANAGEMENT LLC 02/14/2025 520,826 $43.50 M   4.31% 0.49%
NUVEEN ASSET MANAGEMENT, LLC 02/14/2025 519,253 $43.37 M   6.42% 0.49%
BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. 02/12/2025 519,083 $43.35 M   14.20% 0.49%
LORD, ABBETT & CO. LLC 02/14/2025 516,719 $43.16 M   -17.83% 0.49%
ALYESKA INVESTMENT GROUP, L.P. 02/14/2025 451,146 $37.68 M   -51.55% 0.43%
EMERALD ADVISERS, LLC 02/11/2025 438,066 $36.59 M   -0.73% 0.41%
WALLEYE CAPITAL LLC 02/13/2025 383,591 $32.04 M   53.81% 0.36%
NATIONALE-NEDERLANDEN POWSZECHNE TOWARZYSTWO EMERYTALNE S.A. 02/18/2025 380,423 $31.77 M   -5.99% 0.36%
GOLDMAN SACHS GROUP INC 02/11/2025 376,417 $31.44 M   -17.46% 0.36%
DRIEHAUS CAPITAL MANAGEMENT LLC 02/14/2025 369,617 $30.87 M   5.78% 0.35%
BANK OF AMERICA CORP /DE/ 02/14/2025 364,370 $30.43 M   -13.76% 0.34%

Intra-Cellular Therapies, Inc. institutional Ownership - FAQ's

During the previous two years, 465 institutional investors and hedge funds held shares of Intra-Cellular Therapies, Inc.. The most heavily invested institutionals were:

FIRST HAWAIIAN BANK: 0

FULTON BANK, N.A.: 0

FMR LLC: 11.08 M

VANGUARD GROUP INC: 9.72 M

BlackRock, Inc.: 6.11 M

JPMORGAN CHASE & CO: 5.13 M

91.46% of Intra-Cellular Therapies, Inc. stock is owned by institutional investors.

Institutional investors have bought a total of 114.11 M shares in the last 24 months. This purchase volume represents approximately $15.05 B in transactions.